Compare Renascience, Inc. with Similar Stocks
Dashboard
1
Poor Management Efficiency with a low ROE of 0%
- The company has reported losses. Due to this company has reported negative ROE
2
Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -238.51
3
Poor long term growth as Operating profit has grown by an annual rate 0.90% of over the last 5 years
4
The company has declared Negative results for the last 4 consecutive quarters
5
Risky -
Stock DNA
Pharmaceuticals & Biotechnology
JPY 21,575 Million (Small Cap)
NA (Loss Making)
NA
0.00%
-1.02
-9.07%
6.49
Revenue and Profits:
Net Sales:
29 Million
(Quarterly Results - Mar 2026)
Net Profit:
-83 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
0.72%
0%
0.72%
6 Months
-23.21%
0%
-23.21%
1 Year
-58.93%
0%
-58.93%
2 Years
297.18%
0%
297.18%
3 Years
158.04%
0%
158.04%
4 Years
258.92%
0%
258.92%
5 Years
0%
0%
0.0%
Renascience, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
1.17%
EBIT Growth (5y)
0.90%
EBIT to Interest (avg)
-268.11
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.05
Sales to Capital Employed (avg)
0.07
Tax Ratio
0.33%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
9.04
EV to EBIT
-66.04
EV to EBITDA
-66.05
EV to Capital Employed
-19419.22
EV to Sales
181.58
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-10.67%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY
Mar'26
Mar'25
Change(%)
Net Sales
28.60
66.90
-57.25%
Operating Profit (PBDIT) excl Other Income
-101.70
-38.90
-161.44%
Interest
0.00
0.00
Exceptional Items
0.00
-1.20
100.00%
Consolidate Net Profit
-83.00
-40.70
-103.93%
Operating Profit Margin (Excl OI)
-3,563.40%
-581.40%
-298.20%
USD in Million.
Net Sales
YoY Growth in quarter ended Mar 2026 is -57.25% vs -8.86% in Mar 2025
Consolidated Net Profit
YoY Growth in quarter ended Mar 2026 is -103.93% vs -13.37% in Mar 2025
Annual Results Snapshot (Consolidated) - Mar'26
Mar'26
Mar'25
Change(%)
Net Sales
68.60
132.70
-48.30%
Operating Profit (PBDIT) excl Other Income
-356.90
-178.80
-99.61%
Interest
0.00
0.00
Exceptional Items
0.00
322.80
-100.00%
Consolidate Net Profit
-301.30
113.40
-365.70%
Operating Profit Margin (Excl OI)
-5,205.90%
-1,347.70%
-385.82%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2026 is -48.30% vs -31.67% in Mar 2025
Consolidated Net Profit
YoY Growth in year ended Mar 2026 is -365.70% vs 143.90% in Mar 2025
About Renascience, Inc. 
Renascience, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






